CMS Open Payments · Program Year 2024
Retropsoas Technologies, LLC
Retropsoas Technologies, LLC reported $14,599.71 across General Payments, Research, and Ownership to 12 physicians and teaching hospitals across 12 transactions.
- $14.6K Below-median payer
- All-tracks total
- 12 Below-median volume
- Transactions
- 12 Below-median reach
- Recipients
- #1583
- of 1,925 companies
Retropsoas Technologies, LLC reported $14,599.71 across all CMS Open Payments tracks (General + Research + Ownership) to 12 physicians and teaching hospitals in Program Year 2024 - ranking #1583 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $14,599.71, averaging $1.2K per recipient.
Retropsoas Technologies, LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer retropsoas-technologies-llc Retropsoas Technologies, LLC
$14.6K · #1583/1,925 · 0.0% industry · PY2024
- TOT $14.6K
- RANK #1583
- SHARE 0.0%
- TXN 12
- RCP 12
- CAT 3
- GEN $14.6K
- TOP1 69.7%
- PY 2024
Volume peers
Nearest volume peer: North American Rescue, LLC ($14.6K)
Retropsoas Technologies, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Retropsoas Technologies, LLC
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Retropsoas Technologies, LLC that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Consulting Fee" leads the 3-category general-payment breakdown below at $12.0K (82.2% of General Payments, 4 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Consulting Fee" leads Retropsoas Technologies, LLC's 3-category general-payment breakdown at $12.0K, 82.2% of the reported total.
How Retropsoas Technologies, LLC divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $12.0K | 4 | 82.2% |
| Travel and Lodging | $1.6K | 3 | 10.9% |
| Food and Beverage | $1.0K | 5 | 6.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $14,599.71 (100.0%) of $14,599.71 in this company's General Payments records across 4 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Retropsoas Technologies, LLC
The five named recipients with the highest reported General Payments from this company
- 1
John Mangan
$10,169.05 across 9 reported transactions
- 2
Chen Xu
$4,000.00 across 1 reported transactions
- 3
Donald Whiting
$215.33 across 1 reported transactions
- 4
Alexander Yu
$215.33 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Retropsoas Technologies, LLC ranks #1583 of 1,925 by total payments (bottom 18% by spend) but is notably more concentrated than that alone would suggest -- #292 of 1,838 by HHI (top 16% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Biotest AG : $14.7K total payments, HHI 5643
- Atos Medical Inc : $110.5K total payments, HHI 5624
- Zerigo Health, Inc. : $7.5K total payments, HHI 5622
- Medivation Services LLC : $192.46 total payments, HHI 5620
- Inpeco North America, Inc : $7.5K total payments, HHI 5612
- FFF Enterprises, Inc. : $3.6K total payments, HHI 5610
- Retropsoas Technologies, LLC (this company) : $14.6K total payments, HHI 5606
- Ipsen Biopharm Limited : $13.1K total payments, HHI 5603
- BlueRock Therapeutics LP : $405.9K total payments, HHI 5593
- Nidek Co., Ltd. : $29.8K total payments, HHI 5592
- DiaSorin Inc. : $371.5K total payments, HHI 5574
- Bavarian Nordic A/S : $68.0K total payments, HHI 5563
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Retropsoas Technologies, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Retropsoas Technologies, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Retropsoas Technologies, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Circle Cardiovascular Imaging Inc.
Kub Technologies Inc.
Celltrion Healthcare Canada Ltd.
Medela AG
Aytu BioPharma, Inc.
Put this to use
Retropsoas Technologies, LLC ranks #1583 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Retropsoas Technologies, LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.